An APOA1 promoter polymorphism is associated with cognitive performance in patients with multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 2, 2009, Pages 174-179

  Koutsis, G ^a   Panas, M ^a   Giogkaraki, E ^a   Karadima, G ^a   Sfagos, C ^a   Vassilopoulos, D ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

APOA1; Cognitive impairment; Multiple sclerosis; Stroop; Verbal fluency

Indexed keywords

APOLIPOPROTEIN A1;

ADULT; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GREECE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TEST; PROMOTER REGION; WORD LIST RECALL;

ADULT; APOLIPOPROTEIN A-I; COGNITION; COGNITION DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GREECE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; VERBAL LEARNING;

EID: 59349097653     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508097217     Document Type: Article

References (32)

1. Rao SM Leo GJ Bernardin L Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurology 1991; 41: 685-691.
2. Bobholz JA Rao SM. Cognitive dysfunction in multiple sclerosis: A review of recent developments. Curr Opin Neurol 2003; 16: 283-288.
3. Huijbregts SC Kalkers NF de Sonneville LM de Groot V Reuling IE Polman CH. Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS. Neurology 2004; 63: 335-339.
4. Achiron A Barak Y. Cognitive impairment in probable multiple sclerosis. J Neurol Neurosurg Psychiatry 2003; 74: 443-446.
5. Kujala P Portin R Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up study. Brain 1997; 120: 289-297.
6. Oliveri RL Cittadella R Sibilia G. APOE and risk of cognitive impairment in multiple sclerosis. Acta Neurol Scand. 1999; 100: 290-295.
7. Koutsis G Panas M Giogkaraki E. APOE ε4 is associated with impaired verbal learning in patients with MS. Neurology 2007; 68: 546-549.
8. Shi J Zhao C Vollmer TL Tyry TM Kuniyoshi SM. APOE ε4 is associated with cognitive impairment in patients with multiple sclerosis. Neurology 2008; 70: 185-190.
9. Parmenter BA Denney DR Lynch SG Middleton LS Harlan LM. Cognitive impairment in patients with multiple sclerosis: Association with the APOE gene and promoter polymorphisms. Mult Scler 2007; 13: 25-32.
10. Saczynski JS White L Peila RL Rodriguez BL Launer LJ. The relation between apolipoprotein A-I and dementia. The Honolulu-Asia aging study. Am J Epidemiol 2007; 165: 985-992.
11. Merched A Xia Y Visvikis S Serot JM Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol Aging 2000; 21: 27-30.
12. Kuriyama M Takahashi K Yamano T. Low levels of serum apolipoprotein AI and AII in senile dementia. Jpn J Psychiatry Neurol 1994; 48: 589-593.
13. Groenendijk M Cantor RM de Bruin TWA Dallinga-Thie GM. The apoAI-CIII-AIV gene cluster. Atherosclerosis 2001; 157: 1-11.
14. Polman CH Reingold SC Edan G. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005; 58: 840-846.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
16. Boringa JB Lazeron RH Reuling IE. The brief repeatable battery of neuropsychological tests: Normative values allow application in multiple sclerosis clinical practice. Mult Scler 2001; 7: 263-267.
17. Stroop JR. Studies of interference in serial verbal reactions. J Exp Psychol 1935; 18: 643-662.
18. Amato MP Portacccio E Goretti B. The Rao's brief repeatable battery and Stroop test: Normative values with age, education and gender corrections in an Italian population. Mult Scler 2006; 12: 787-793.
19. Beck AT Ward CH Mendelson M Mock J Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
20. Dallinga-Thie GM Bu XD van Linde-Sibenius Trip M Rotter JI Lusis AJ de Bruin TW. Apolipoprotein A-I/C-III/A-IV gene cluster in familial combined hyperlipidemia: Effects on LDL-cholesterol and apolipoproteins B and C-III. J Lipid Res 1996; 37: 136-147.
21. Amato MP Zipoli V Goretti B. Benign multiple sclerosis. Cognitive, psychological and social aspects in a clinical cohort. J Neurol 2006; 253: 1054-1059.
22. Harr SD Uint L Hollister R Hyman BT Mendez AJ. Brain expression of apolipoproteins E, J and A-I in Alzheimer's disease. J Neurochem 1996; 66: 2429-2435.
23. Winiewski T Golabek AA Kida E Wisniewski KE Frangione B. Comformational mimicry in Alzheimer's disease. Role of apolipoproteins in amyloidogenesis. Am J Pathol 1995; 147: 238-244.
24. Remaley AT Stonik JA Demosky SJ. Apolipoprotein specificity for lipid efflux by the human ABCA1 transporter. Biochim Biophys Res Commun 2001; 280: 818-823.
25. Vollbach H Heun R Morris CM. APOA1 promoter polymorphism influences risk of early-onset nonfamiliar AD. Ann Neurol 2005; 58: 436-441.
26. Boyles JK Zoellner CD Anderson LJ. A role for apolipoprotein E, apolipoprotein A-I and low density lipoprotein receptors in cholesterol transport during regeneration and remyelination of the rat sciatic nerve. J Clin Invest 1989; 83: 1015-1031.
27. Gelman BB Goodrum J Bouldin TW. Macrophage apolipoprotein synthesis and endoneurial distribution as a result of segmental demeyelination. J Neuropathol Exper Neurol 1991; 50: 383-407.
28. Jurado MB Rosselli M. The elusive nature of executive functions: A review of our current understanding. Neuropsychol Rev 2007; 17: 213-233.
29. Desmond DW. The neuropsychology of vascular cognitive impairment: Is there a specific cognitive deficit. J Neurol Sci 2004; 226: 3-7.
30. Looi JCL Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999; 53: 670-678.
31. Schultz JR Verstuyft JG Gong EL Nichols AV Rubin EM. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993; 365: 762-764.
32. Luc G Bard JM Ferrieres J.: On behalf of the PRIME Study Group. Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I and lipoprotein A-I/ A-II in prediction of coronary heart disease: The PRIME study. Arterioscler Thromb Vasc Biol 2002; 22: 1155-1161.